Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $47.8 million.

  • Ani Pharmaceuticals' Free Cash Flow rose 395.33% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.7 million, marking a year-over-year increase of 102.84%. This contributed to the annual value of $47.8 million for FY2024, which is 56.60% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Free Cash Flow stood at $47.8 million for FY2024, which was down 56.60% from $110.1 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Free Cash Flow peaked at $110.1 million during FY2023, and registered a low of -$40.1 million during FY2022.
  • In the last 3 years, Ani Pharmaceuticals' Free Cash Flow had a median value of $47.8 million in 2024 and averaged $39.3 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 5,339.08% in 2022, then skyrocketed by 374.68% in 2023.
  • MRY analysis of 5 years shows Ani Pharmaceuticals' Free Cash Flow stood at $9.1 million in 2020, then crashed by 91.62% to $765,000 in 2021, then crashed by 5,339.08% to -$40.1 million in 2022, then skyrocketed by 374.68% to $110.1 million in 2023, then plummeted by 56.60% to $47.8 million in 2024.
  • Its last three reported values are $47.8 million in FY2024, $110.1 million for FY2023, and -$40.1 million during FY2022.